Leveraging Biomarkers for Personalized Treatment of Alcohol Use Disorder Comorbid With PTSD
Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
This is a double-blind, 2-group randomized controlled trial evaluating the effects of
topiramate versus placebo in patients with comorbid PTSD and moderate-to-severe AUD. This
trial will provide one of the first rigorous tests of whether the effects of topiramate in
AUD generalize to patients with co-occurring PTSD, and one of the first rigorous tests of
whether topiramate has beneficial effects on PTSD symptoms in this population. It will be the
first study to test whether the rs2832407 genotype predicts clinical response to topiramate
for AUD and PTSD in patients with both disorders. Further, it will contribute to the
understanding of topiramate's mechanisms of action in the co-morbid AUD/PTSD population, and
to the discovery of predictors of treatment response.
Phase:
Phase 2
Details
Lead Sponsor:
New York University School of Medicine NYU Langone Health
Collaborator:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)